Pipeline
Advancing targeted anti-infective candidates
PALDARA’s pipeline is built around next-generation bacteriophage therapeutics and biomaterial delivery platforms designed to address multidrug-resistant infections with precision, adaptability, and translational focus.
Programs
Core pipeline priorities
Our development strategy integrates phage biology, biomaterial science, and translational research to support targeted antibacterial interventions across high-need clinical settings.
Phage therapeutics
Engineered and selected bacteriophage candidates designed to target clinically relevant bacterial pathogens with high specificity.
Hydrogel delivery
Advanced biomaterial platforms intended to localize therapy, improve retention at the site of infection, and support controlled release.
AMR prevention
Programs focused on preventing colonization and recurrence in environments where resistant organisms create persistent treatment challenges.
Translational studies
Preclinical and development activities that evaluate efficacy, delivery performance, and readiness for future clinical advancement.
Platform
Built for precision delivery
PALDARA’s proprietary phage-hydrogel approach is designed to pair targeted antibacterial activity with localized biomaterial delivery, supporting therapeutic performance where conventional antibiotics may fall short.
Targeted action
Phage-based candidates are selected to engage specific bacterial threats while helping reduce unnecessary broad-spectrum exposure.
Localized retention
Hydrogel-enabled delivery is intended to improve persistence at the treatment site and support practical deployment in complex infection settings.
Focus Areas
Where the pipeline is headed
The pipeline is organized around therapeutic areas where targeted antibacterial approaches and advanced delivery technologies may offer meaningful clinical value.
